Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-γ gene into lung cancer

被引:22
作者
Noguchi, M
Imaizumi, K
Kawabe, T
Wakayama, H
Horio, Y
Sekido, Y
Hara, T
Hashimoto, N
Takahashi, M
Shimokata, K
Hasegawa, Y [1 ]
机构
[1] Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Sch Med, Dept Pathol, Nagoya, Aichi 4668550, Japan
关键词
antitumor immunity; CD40; ligand; interferon-gamma; cytotoxic T lymphocyte; lung cancer;
D O I
10.1038/sj.cgt.7700320
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
CD40-CD40 ligand (CD40L) interaction is an Important costimulatory signaling pathway in the crosstalk between T cells and antigen-presenting cells. This receptor-ligand system is known to be essential in eliciting strong cellular immunity. Here we demonstrate that murine lung cancer cells (3LLSA) transduced with the CD40L gene (3LLSA-CD40L) were rejected in syngeneic C57BL/6 mice, but grew in CD40-deficient mice to the same extent as control tumor cells. Immunohistochemical study showed that inflammatory cells, including CD4+, CD8+ T cells and NK cells, infiltrated Into the inoculated 3LLSA-CD40L tumor tissue. Inoculation of 3LLSA-CD40L cells into mice resulted in the induction of 3LLSA-specific cytotoxic T-cell immunity, and the growth of parental 3LLSA tumors was inhibited when 3LLSA cells were inoculated into C57BL/6 mice mixed with 3LLSA-CD40L cells or when they were rechallenged 4 weeks after 3LLSA-CD40L cells were rejected. Furthermore, co-inoculation of interferon (IFN)-gamma -transduced cells (3LLSA-IFN gamma) with 3LLSA-CD40L cells enhanced the antitumor immunity efficiently in vivo. These results indicate that the in vivo priming with CD40L- and IFN-gamma gene-transduced lung cancer cells is a promising strategy for inducing antitumor immunity in the treatment of lung cancer.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 37 条
[31]   High-level IL-12 production by human dendritic cells requires two signals [J].
Snijders, A ;
Kalinski, P ;
Hilkens, CMU ;
Kapsenberg, ML .
INTERNATIONAL IMMUNOLOGY, 1998, 10 (11) :1593-1598
[32]   Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 [J].
Sotomayor, EM ;
Borrello, I ;
Tubb, E ;
Rattis, FM ;
Bien, H ;
Lu, ZB ;
Fein, S ;
Schoenberger, S ;
Levitsky, HI .
NATURE MEDICINE, 1999, 5 (07) :780-787
[33]   Induction of antigen-specific T cell anergy: An early event in the course of tumor progression [J].
Staveley-O'Carroll, K ;
Sotomayor, E ;
Montgomery, J ;
Borrello, I ;
Hwang, L ;
Fein, S ;
Pardoll, D ;
Levitsky, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (03) :1178-1183
[34]   Functions of CD40 on B cells, dendritic cells and other cells [J].
vanKooten, C ;
Banchereau, J .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (03) :330-337
[35]   The great escape: Is immune evasion required for tumor progression? [J].
Villunger, A ;
Strasser, A .
NATURE MEDICINE, 1999, 5 (08) :874-875
[36]   Tumor expression of Fas ligand (CD95L) and the consequences [J].
Walker, PR ;
Saas, P ;
Dietrich, PY .
CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (05) :564-572
[37]   Human tumor antigens for cancer vaccine development [J].
Wang, RF ;
Rosenberg, SA .
IMMUNOLOGICAL REVIEWS, 1999, 170 :85-100